Study Protocol
Prospective evaluation of immunological, molecular-genetic, image-based and microbial analyses to characterize tumor response and control in patients with unresectable stage III NSCLC treated with concurrent chemoradiotherapy followed by consolidation therapy with durvalumab (PRECISION): protocol for a prospective longitudinal biomarker study
Lukas Käsmann, Julian Taugner, Chukwuka Eze, Alexander Nieto, Carolyn Pelikan, Benedikt Flörsch, Saskia Kenndoff, Thomas P. Hofer, Elfriede Nössner, Christian Schulz, Marcus Unterrainer, Amanda Tufman, Frederick Klauschen, Andreas Jung, Jens Neumann, Jörg Kumbrink, Niels Reinmuth, Peter Bartenstein, Claus Belka, Farkhad Manapov
